Last reviewed · How we verify

BE-PEP Bedaquiline

Institute of Tropical Medicine, Belgium · Phase 3 active Small molecule

Bedaquiline inhibits bacterial ATP synthase, disrupting energy production in Mycobacterium tuberculosis.

Bedaquiline inhibits bacterial ATP synthase, disrupting energy production in Mycobacterium tuberculosis. Used for Multidrug-resistant tuberculosis (MDR-TB), Extensively drug-resistant tuberculosis (XDR-TB).

At a glance

Generic nameBE-PEP Bedaquiline
SponsorInstitute of Tropical Medicine, Belgium
Drug classATP synthase inhibitor
TargetMycobacterial ATP synthase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Bedaquiline is a diarylquinoline that binds to the ATP synthase enzyme of tuberculosis bacteria, blocking ATP synthesis and causing rapid bactericidal activity. This mechanism is distinct from existing TB drugs and is effective against both drug-susceptible and multidrug-resistant tuberculosis strains. BE-PEP likely refers to a bedaquiline-containing combination regimen being evaluated in Phase 3 trials.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: